Guide
Specialty careTechnologyHospital: Peking University People's Hospital

Beijing Protocol: haploidentical hematopoietic stem cell transplant

Haploidentical stem cell transplant

  • Acute leukemia
  • Severe aplastic anemia

Some evidence dates from earlier years. Confirm the latest information with the hospital.

At a glance

A haploidentical donor hematopoietic stem cell transplant system covering leukemia and severe aplastic anemia.

Why here

  • Uses haploidentical (partially matched) donors, widening donor availability compared with fully matched transplant.
  • A non-ex-vivo T-cell-depleted haploidentical transplant system built around immune tolerance and immune reconstitution.
  • The system has been adopted by multiple centres in China and extended to centres in Italy, France and elsewhere.
  • Covers transplant indications including leukemia and severe aplastic anemia, with individualised protocols by disease, condition and age.

Evidence and data

3-year overall survival 74–79% for leukemia treated with haploidentical transplant

Population
Leukemia patients receiving haploidentical hematopoietic stem cell transplant
Data year
2021 Update pending
Source type
Hospital official statement

www.pkuph.edu.cn

Hospital-published statement/public data. Not a treatment promise; outcomes vary.

3-year overall survival 86–89% for severe aplastic anemia treated with haploidentical transplant

Population
Patients with severe aplastic anemia receiving haploidentical transplant
Data year
2021 Update pending
Source type
Hospital official statement

www.pkuph.edu.cn

Hospital-published statement/public data. Not a treatment promise; outcomes vary.

Related work cited in 40 international guidelines/consensus statements (Europe/US and other regions)

Population
Research on the Beijing Protocol (non-ex-vivo T-cell-depleted haploidentical transplant)
Data year
2021 Update pending
Source type
Hospital official statement

www.pkuph.edu.cn

Hospital-published statement/public data. Not a treatment promise; outcomes vary.

More than 100 centres in China have implemented the Beijing Protocol

Population
Medical institutions in China performing haploidentical transplant
Data year
2021 Update pending
Source type
Hospital official statement

www.pkuph.edu.cn

Hospital-published statement/public data. Not a treatment promise; outcomes vary.

Suitable and not suitable

Suitable
Requires hospital assessment based on disease type, disease status, age and donor status.
Not suitable
Not for self-assessment; eligibility is determined by the hospital.

This is not a self-assessment tool; the hospital decides on eligibility after review.

Treatment and stay

Usually includes pre-transplant assessment, donor preparation and collection, transplant with inpatient monitoring, and post-discharge follow-up. The actual stay must be assessed by the hospital for each case.

  1. Pre-treatment assessment
  2. Treatment / procedure
  3. Inpatient observation
  4. Follow-up

The actual stay must be assessed by the hospital for each case. Read the care process

Cost range

No public data yet — we update this as hospitals publish information.

Typical cost components to discuss with the hospital:

  • Medication and cell preparation
  • Transplant / infusion
  • Hospital stay and monitoring
  • Tests and laboratory work
  • Follow-up visits
  • Management of complications

Published item prices are not a total treatment price. A case-specific estimate must come from the hospital.

International patients

International patient acceptance is to be confirmed with the hospital.

Sources and updates

Last reviewed:

Compiled from the hospital's official website · https://www.pkuph.edu.cn/zltes_detai/15784.html · Compiled on: 2026-10-23

1 update record(s)
  • · Added

Frequently asked questions

How is haploidentical transplant different from a matched transplant?
A haploidentical transplant uses a half-matched donor (often a parent, child or sibling), while a matched transplant requires a fully HLA-matched donor. The transplant team decides based on the condition and matching results.
Where does the donor come from, and do family members need matching tests?
Donors are usually sought among family members with HLA matching tests. If no suitable family donor is found, the hospital assesses other donor sources. Matching and selection are arranged by the transplant team.
What is the risk of graft-versus-host disease (GVHD), and how is it managed?
GVHD is a complication that requires monitoring after transplant; risk and symptoms vary by patient. Hospitals usually have prevention, monitoring and treatment protocols; the transplant team assesses the specific risk and management.
What preparation is needed before transplant?
Preparation usually includes medical records and test results, infection screening, organ-function assessment, psychological assessment, and non-medical arrangements such as visa and travel. The hospital provides the specific checklist after assessment.
How long is the hospital stay, and what should be monitored after discharge?
The hospital stay varies with the transplant plan, donor situation and complications. After discharge, follow-up, infection prevention and medication management are usually needed; the hospital decides based on recovery.
How can international patients start?
Start by preparing diagnosis, medical records and test results, then use the hospital or our planning tool to understand remote assessment and travel arrangements. See the visa guide for visa and invitation-letter requirements. Acceptance and arrangements are confirmed by the hospital.

Credential basis

  • Haploidentical hematopoietic stem cell transplant · Hospital-reported · Verified: 2026-10-23 · Source

This is reference information about the hospital, not an authorization, partnership or recommendation. Verify current status with the hospital.

Other specialties at this hospital

Plan your trip around this specialty

Use the planning tool to compare cities and see what information is available for your passport.

Start planningAsk a questionCheck report coverage